Equities

CH Biotech R&D Co Ltd

6534:TAI

CH Biotech R&D Co Ltd

Actions
Basic MaterialsChemicals
  • Price (TWD)81.40
  • Today's Change0.40 / 0.49%
  • Shares traded24.02k
  • 1 Year change+1.37%
  • Beta--
Data delayed at least 20 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments943530321
Total Receivables, Net10634161
Total Inventory119177103
Prepaid expenses63022
Other current assets, total3.766347
Total current assets1,235804655
Property, plant & equipment, net2,3612,3652,358
Goodwill, net2.452.452.45
Intangibles, net3.715.825.39
Long term investments29----
Note receivable - long term------
Other long term assets14165.65
Total assets3,6493,1953,029
LIABILITIES
Accounts payable9.269.6221
Accrued expenses------
Notes payable/short-term debt190120188
Current portion long-term debt/capital leases414142158
Other current liabilities, total269196163
Total current liabilities882468529
Total long term debt241633777
Total debt8458951,122
Deferred income tax02.560
Minority interest------
Other liabilities, total5.364.26--
Total liabilities1,1291,1081,306
SHAREHOLDERS EQUITY
Common stock1,028971844
Additional paid-in capital718331331
Retained earnings (accumulated deficit)771782570
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total3.303.16(23)
Total equity2,5202,0881,723
Total liabilities & shareholders' equity3,6493,1953,029
Total common shares outstanding1039797
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.